Dr. McGuire is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-8000Fax+1 214-645-7269
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1997 - 2001
- Duke University School of MedicineM.H.S., Clinical Research Training Program, 1998 - 2000
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1993 - 1996
- Johns Hopkins University School of MedicineClass of 1993
- Hendrix CollegeB.A., Chemistry, Summa Cum Laude, 1985 - 1989
Certifications & Licensure
- TX State Medical License 1994 - 2026
- NC State Medical License 1996 - 2002
- VA State Medical License 1999 - 2000
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FESC) European Society of Cardiology
- Fellow (FAHA) AHA
- Regents Outstanding Teacher Award University of Texas Board of Regents, 2013
- Join now to see all
Clinical Trials
- Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride Start of enrollment: 2005 Feb 01
Publications & Presentations
PubMed
- Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.Adam J Nelson, Lisa A Kaltenbach, Darren K McGuire, Monica Levya, Hussein R Al-Khalidi
American Heart Journal. 2025-04-01 - Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of...Matthew M Y Lee, Nazim Ghouri, Anoop Misra, Yu Mi Kang, Martin K Rutter
Diabetes Care. 2025-03-01 - 1 citationsEffect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter
The Lancet. Diabetes & Endocrinology. 2025-02-13
Journal Articles
- Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with DiabetesMichael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
- Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 DiabetesDarren K Mcguire, Samuel Dagogo-Jack, Urszula Masiukiewicz, JAMA Cardiology
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A1C : Glucose management in type 2 diabetes mellitus.Goyal A, Kosiborod M, McGuire DK, Garber AJ, American College of Cardiology Foundation Diabetes Self-Assessment Program, Washington, DC, 1/1/2011
Lectures
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...Scientific Sessions 2008, New Orleans, Louisiana, USA
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...Scientific Sessions 2007, Orlando, Florida, USA
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...International Chair on Cardiometabolic Risk, 2nd International Congress on Abdominal Obesity, Buenos
- Join now to see all
Other
- The TECOS Trial of Sitagliptin vs. Placebo: Context and Cardiovascular Observations.Gore MO, McGuire DK
http://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/19/the-tecos-trial-of-sitagliptin-vs-placebo
1/23/2015 - MY APPROACH to Sulfonylureas in Patients With Coronary Artery Disease.McGuire DK, Gore O, PracticeUpdate
http://www.practiceupdate.com/ExpertOpinion/1088/1/8
1/10/2014 - Consultant Live Podcast: DPP 4 InhibitorsMcGuire DK
http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2129971
1/27/2013 - Join now to see all
Authored Content
- Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular DiseaseJune 2020
- Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
Press Mentions
- The Physicians Really Are Healing Themselves, with OzempicFebruary 10th, 2025
- Anti-Obesity Drugs Show Whole-Body Promise and More Is AheadOctober 29th, 2024
- Not Just Weight Loss, Ozempic Also Has Heart Health BenefitsMay 4th, 2023
- Join now to see all
Grant Support
- Rosiglitazone VS Placebo: Effect Of CV Performance And Myocardial TriglycerideNational Center For Research Resources2005–2007
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: